PENDING PATENTSBioWorld Today here continues its occasional listings of governmentagencies seeking industrial licensees to commercialize their biotech-related research and development inventions. Commercializationrights are offered by the National Institutes of Health, Office ofTechnology Transfer (OTT). Announcements of the following sixopportunities were published in recent weeks in the Federal Register.
To obtain licensing information, and copies of the pending U.S.patent applications listed below, contact OTT licensing specialistsindicated.
National Institute Of Diabetes, Digestive & Kidney Diseases
Chromatin Insulator For Human Gene Therapy
DNA fragment protects expressed genes from cis-acting regulatorysequences in mammalian cells, for transgenic technologies andhuman gene therapies. "Invention may represent large potentialsavings for licensees constructing transgenic cell lines or animals."
Application: 08/283,125
Filed: 7/29/94
Inventors: J.H. Chung, et al.
Contact: Joseph Contrera, (301) 496-7056, ext. 244
National Cancer Institute
Azo Dye Derivatives Combat HIV Infection
Pure preparation of azo stilbenes displays broad antiviral activity,including HIV. Previously, such antiviral dyes resisted purification oftheir anti-HIV compounds.
Application: 08/479,540
Filed: 6/7/95
Inventors: R.D. Haugwitz, et al.
Contact: Cindy Fuchs, (301) 496-7735, ext. 232
Amido-Substituted Anti-HIV Stilbenes
Aroylanaline dye derivatives prevent replication of retroviruses,notably HIV, in human T cells, without staining tissue. Inventionteaches compound synthesis, pharmaceutical formulations, methodsfor treating viral infection.
Application: 08/390,057
Filed: 2/17/95
Inventors: R.D. Haugwitz, et al.
Contact: Gloria Richmond, (301) 496-7056, ext. 268
Hepatitis A Protective Vaccine
Attenuated hepatitis A virus (HAV), mutant of wild-type strain,elicits serum-neutralizing antibody production in chimpanzees,hence, is suitable for human vaccine development. Immune serumglobulin, previously the only vaccine for preventing HAV infection,elicits only low antibody levels, so requires repeated doses.
Application: 007/822,639
Filed: 1/16/92
Inventors: R.H. Purcell, et al.
Contact: Gloria Richmond, (301) 496-7056, ext. 268
Isolating Most-Potent Antigen-Presenting Cell
Dendritic cells excel at presenting antigens to fight infections,including HIV and certain cancers. Method isolates dendritic cells ofunprecedented purity from patient's blood, by leukopheresis aspreliminary step without need for cytokine treatment followed bycountercurrent elutriation.
Application: 08/379,227
Filed: 1/27/95
Inventors: P.A. Cohen, et al.
Contact: Stephen Finley, (301) 496-7735, ext. 215
Angio-Associated Migratory-Cell Protein Binds Heparin
Crystalline peptides derived from AAMP-1 have heparin-binding andcell-adhesive properties. Potential uses include anti-clottingheparinization, wound-healing, cell adhesion to prosthetic devices.
Application: 08/083,945
Filed: 6/25/93
Inventors: M. E. Beckner, et al.
Contact: Susan Rucker, (301) 496-7056, ext. 245
_ Compiled By David N. Leff
(c) 1997 American Health Consultants. All rights reserved.